Prime Medicine Prices $125M Offering at $3.50, a Discount to Monday's Close
PRME sits 41% above its 52-week low of $2.67.
Summary
Prime Medicine priced its underwritten common stock offering at $3.50 a share for 35,714,286 shares, grossing roughly $125 million before the 30-day option for up to 5.4 million additional shares. The price is below the $3.7595 last sale, so buyers are getting a modest discount and existing holders face dilution. Jefferies, TD Cowen and Goldman Sachs are acting as joint book-running managers for the offering, which is expected to close on or about Nov. 12. This follows Monday's launch of the $125 million deal and the 8-K disclosing about $61.2 million of unrestricted cash at September 30 — the raise roughly doubles the balance sheet of a company that has carried a going concern warning. The cash buys runway for the pipeline: PM647 cleared its IND in September and the first patient was dosed in the PM577a Wilson's disease trial in late October.
At the time of this announcement, PRME was trading at $3.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $707.4M. The 52-week trading range was $2.67 to $5.91. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.